vTv Therapeutics (VTVT) EBT (2014 - 2026)
vTv Therapeutics (VTVT) reported EBT of $24.1 million for Q1 2026, up 488.19% on a YoY basis from $4.1 million in Q1 2025, and up 438.11% sequentially from -$7.1 million in Q4 2025.
vTv Therapeutics (VTVT) EBT (2014 - 2026) Analysis & Trends
vTv Therapeutics (VTVT) has 13 years of EBT data on file, last reported at $24.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 488.19% year-over-year to $24.1 million; the trailing twelve-month figure through Mar 2026 stood at -$729000.0 (up 96.82% YoY), and the FY2025 full-year result was -$31.1 million, down 37.49% from the prior year.
- EBT climbed to $24.1 million in Q1 2026, from -$7.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $24.1 million in Q1 2026 to a low of -$10.3 million in Q3 2025.
- A 5-year average of -$4.7 million and a median of -$6.1 million in 2022 frame the typical range for EBT.
- Across the five-year window, EBT tumbled 386.44% in 2022 and jumped 488.19% in 2026, its largest moves.
- Tracing VTVT's EBT over 5 years: stood at -$6.1 million in 2022, then gained by 27.08% to -$4.4 million in 2023, then increased by 0.09% to -$4.4 million in 2024, then tumbled by 60.87% to -$7.1 million in 2025, then soared by 438.11% to $24.1 million in 2026.
- Business Quant data shows VTVT's EBT at $24.1 million in Q1 2026, -$7.1 million in Q4 2025, and -$10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 468.11 Bn | 463.32 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 122.48 Bn | 115.23 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.55 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.66 Bn | 50.47 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.42 Bn | 34.41 Bn | 959.66 Mn | 221.65 Mn |
| 10 | vTv Therapeutics | 18.96 Mn | 18.96 Mn | - | 24.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.13 Mn |
| Dec 31, 2025 | -7.14 Mn |
| Sep 30, 2025 | -10.35 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | -6.22 Mn |
| Dec 31, 2024 | -4.44 Mn |
| Sep 30, 2024 | -5.84 Mn |
| Jun 30, 2024 | -6.41 Mn |
| Mar 31, 2024 | -5.92 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Sep 30, 2023 | -8.54 Mn |
| Jun 30, 2023 | -7.21 Mn |
| Mar 31, 2023 | -5.77 Mn |
| Dec 31, 2022 | -6.09 Mn |
| Sep 30, 2022 | -5.47 Mn |
| Jun 30, 2022 | -4.09 Mn |
| Mar 31, 2022 | -9.22 Mn |
| Dec 31, 2021 | -9.48 Mn |
| Sep 30, 2021 | -1.37 Mn |
| Jun 30, 2021 | -841,000.00 |